Champions Oncology (NASDAQ:CSBR – Get Free Report) and BioLife Solutions (NASDAQ:BLFS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.
Risk and Volatility
Champions Oncology has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.
Valuation and Earnings
This table compares Champions Oncology and BioLife Solutions”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Champions Oncology | $59.42 million | 1.12 | -$1.17 million | ($0.08) | -59.88 |
| BioLife Solutions | $106.69 million | 17.71 | -$4.59 million | $1.16 | 33.28 |
Champions Oncology has higher earnings, but lower revenue than BioLife Solutions. Champions Oncology is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings for Champions Oncology and BioLife Solutions, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
| BioLife Solutions | 0 | 10 | 1 | 0 | 2.09 |
BioLife Solutions has a consensus target price of $31.38, indicating a potential downside of 18.74%. Given BioLife Solutions’ stronger consensus rating and higher probable upside, analysts clearly believe BioLife Solutions is more favorable than Champions Oncology.
Profitability
This table compares Champions Oncology and BioLife Solutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
| BioLife Solutions | 53.29% | 2.70% | 2.49% |
Insider and Institutional Ownership
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 46.3% of Champions Oncology shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
BioLife Solutions beats Champions Oncology on 12 of the 14 factors compared between the two stocks.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
About BioLife Solutions
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
